Prospektivní klinická studie o exosomech odvozených z mezenchymálních kmenových buněk lidské pupečníkové šňůry pro léčbu dětského autismu (EXO-ASD)

Inclusion Criteria:

• Diagnosis meets the ICD-11 ASD criteria or DSM-5 ASD clinical diagnostic standards.
• No significant improvement in core symptoms was observed after ≥3 months of standardized behavioral intervention.
• Score ≥30 on the CARS2, indicating mild-to-moderate or more severe autism.
• Aged 3 (inclusive) to 7 (inclusive) years, regardless of gender
• Voluntary participation in this clinical study, with written informed consent provided by the patient's legal guardian, and willingness to undergo examinations, treatment, and cooperate with follow-up visits.
• In the investigator's judgment, the patient is capable of understanding and complying with study requirements.

Exclusion Criteria:

• History of severe allergic reactions.
• Any severe mental disorder or other types of autism spectrum disorders.
• History of epileptic seizures within the past six months.
• Autism secondary to epilepsy, cerebrovascular disease, or traumatic brain injury.
• Disease severity rated as normal, borderline mental disorder, or mild mental disorder on the Clinical Global Impression scale.
• Moderate or severe extrapyramidal symptoms or tardive dyskinesia.
• Severe self-injurious behavior.
• Active systemic or severe localized infections, including human immunodeficiency virus, syphilis, and hepatitis.
• Autoimmune diseases.
• Major organ impairment.
• Severe pulmonary or hematological diseases, malignancies, or immunodeficiency.
• Concurrent treatments that may interfere with the safety and efficacy evaluation of stem cell therapy.
• Participation in other clinical trials within the past three months.
• Other clinical conditions deemed by investigators as unsuitable for study inclusion.